Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2No longer available 1

Sponsor Class

OTHER 3NETWORK 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 199Leukemia, Lymphocytic, Chronic, B-Cell 169Leukemia 165Myelodysplastic Syndromes 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 151Lymphoma, Non-Hodgkin 129Lymphoma 120Multiple Myeloma 112Hodgkin Disease 110Lymphoma, Follicular 97Lymphoma, Mantle-Cell 95Lymphoma, Large B-Cell, Diffuse 87Lymphoma, B-Cell, Marginal Zone 79Myeloproliferative Disorders 77Burkitt Lymphoma 75Congenital Abnormalities 73Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Leukemia, Myelomonocytic, Chronic 66Leukemia, Myeloid, Chronic-Phase 64Leukemia, Myeloid, Accelerated Phase 62Recurrence 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 50Anemia, Refractory, with Excess of Blasts 50Primary Myelofibrosis 48Neoplasms, Plasma Cell 47Blast Crisis 47Hematologic Neoplasms 40Leukemia, Prolymphocytic 37Dendritic Cell Sarcoma, Interdigitating 37

Interventions

fludarabine 4Cyclophosphamide 4fludarabine phosphate 3AP 1903 reagent 3Bendamustine Hydrochloride 2pembrolizumab 1isatuximab 1ibritumomab tiuxetan 1Rituximab 1Radiotherapy 1Pharmacogenomic Testing 1Melphalan 1Lenalidomide 1Etoposide 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Immunoproliferative Disorders × fludarabine phosphate × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03594162 2021-12-03

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer Center

No longer available
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡